Table of Content

1. Introduction


2. Research Methodology


3. Executive Summary


4. Market Dynamics

4.1 Growth Drivers
4.2 Challenges


5. Global Liver Disease Therapeutic Market


6. Global Liver Disease Therapeutic Market Share Analysis

6.1 Therapy Type
6.2 Disease Type
6.3 End Users
6.4 Country


7. Therapy Type

7.1 Anti-Rejection Drugs/Immunosuppressants
7.2 Chemotherapy Drugs
7.3 Targeted therapy
7.4 Vaccines
7.5 Immunoglobulins
7.6 Corticosteroids
7.7 Anti-Viral Drugs


8. Disease Type

8.1 Non-alcoholic Fatty Liver Disease (NAFLD)
8.2 Viral Hepatitis (B, C, D)
8.3 Alcoholic Liver Disease (ALD)
8.4 Autoimmune Liver Disease (ALD)


9. End Users

9.1 Hospitals
9.2 Laboratories
9.3 Others


10. Country

10.1 North America

10.1.1 United States
10.1.2 Canada

10.2 Europe

10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherlands
10.2.8 Turkey

10.3 Asia Pacific

10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Thailand
10.3.6 Malaysia
10.3.7 Indonesia
10.3.8 Australia
10.3.9 New Zealand

10.4 Latin America

10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina

10.5 Middle East & Africa

10.5.1 Saudi Arabia
10.5.2 UAE
10.5.3 South Africa


11. Porter’s Five Analysis

11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes


12. SWOT Analysis

12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat


13. Market Outlook and Opportunities

13.1 Emerging Technologies
13.2 Future Market Trends
13.3 Investment Opportunities


14. Company Analysis – Global Liver Disease Therapeutic Market

14.1 Abbott Laboratories

14.1.1 Overview
14.1.2 Recent Development
14.1.3 Product Portfolio & Product Launch in Last 1 Year
14.1.4 Revenue

14.2 Astellas Pharma Inc.

14.2.1 Overview
14.2.2 Recent Development
14.2.3 Product Portfolio & Product Launch in Last 1 Year
14.2.4 Revenue

14.3 Bristol-Mayers Squibb

14.3.1 Overview
14.3.2 Recent Development
14.3.3 Product Portfolio & Product Launch in Last 1 Year
14.3.4 Revenue

14.4 Gilead Sciences

14.4.1 Overview
14.4.2 Recent Development
14.4.3 Product Portfolio & Product Launch in Last 1 Year
14.4.4 Revenue

14.5 GlaxoSmithKline Pharmaceuticals Ltd

14.5.1 Overview
14.5.2 Recent Development
14.5.3 Product Portfolio & Product Launch in Last 1 Year
14.5.4 Revenue

14.6 F. Hoffmann-La Roche Ltd

14.6.1 Overview
14.6.2 Recent Development
14.6.3 Product Portfolio & Product Launch in Last 1 Year
14.6.4 Revenue

14.7 Merck & Co. Inc

14.7.1 Overview
14.7.2 Recent Development
14.7.3 Product Portfolio & Product Launch in Last 1 Year
14.7.4 Revenue

14.8 Novartis AG

14.8.1 Overview
14.8.2 Recent Development
14.8.3 Product Portfolio & Product Launch in Last 1 Year
14.8.4 Revenue

14.9 Sanofi S.A

14.9.1 Overview
14.9.2 Recent Development
14.9.3 Product Portfolio & Product Launch in Last 1 Year
14.9.4 Revenue

14.10 Pfizer Inc.

14.10.1 Overview
14.10.2 Recent Development
14.10.3 Product Portfolio & Product Launch in Last 1 Year
14.10.4 Revenue

14.11 Takeda Pharmaceuticals

14.11.1 Overview
14.11.2 Recent Development
14.11.3 Product Portfolio & Product Launch in Last 1 Year
14.11.4 Revenue